Key Highlights
- Pharma giant Pfizer Inc.
- (NYSE:PFE)’s shares are down by 4.7% over the past year and flat year-to-date.
- UBS initiated coverage of the stock in January as it set a Neutral rating for the shares and a $25 share price target.
- UBS explained that between $15 billion to $20 billion in Pfizer Inc.
- (NYSE:PFE)’s revenue is tied to drugs that will lose patent protection over the next three years.